Cost-Utility Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-To-Severe Active Rheumatoid Arthritis In Greece
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2624
https://www.valueinhealthjournal.com/article/S1098-3015(14)04573-2/fulltext
Title :
Cost-Utility Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-To-Severe Active Rheumatoid Arthritis In Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04573-2&doi=10.1016/j.jval.2014.08.2624
First page :
A382
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
328